• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cyanotech Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

    5/8/25 3:56:11 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CYAN alert in real time by email
    cyan20250508_8k.htm
    false 0000768408 0000768408 2025-05-02 2025-05-02
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    Form 8-K
     
    Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    May 2, 2025
    Date of Report: (Date of earliest event reported)
     
    Cyanotech Corporation
    (Exact name of registrant as specified in its charter)
     
    Nevada
    (State or other jurisdiction of
    incorporation)
    000-14602
    (Commission File Number)
    91-1206026
    (IRS Employer Identification
    Number)
     
     
    73-4460 Queen Kaahumanu Highway, Suite #102, Kailua Kona, HI 96740
    (Address of principal executive offices)
     
    (808) 326-1353
    (Registrant’s telephone number)
     
    Not Applicable
    (Former name or former address, if changed since last report)
     
    Securities registered pursuant to Section 12(b) of the Act: none
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


     
     

     
     
    Item 1.01.
    Entry into a Material Definitive Agreement.
     
    On May 2, 2025, Cyanotech Corporation (the “Company”) entered into a Fourth Amendment (the “Amendment”) to the Amended and Restated Promissory Note with Skywords Family Foundation, Inc. (“Skywords”), dated as of April 12, 2021 and amended on December 14, 2022, August 13, 2023, and August 9, 2024 (the “Note”). The Amendment amends Section 4 to the Note to allow the Company to elect, in its sole discretion, to pay the interest accrued during the fiscal year ended March 31, 2026 in the form of its common stock at a per share value of $1.00 per share. All other terms of the Note remain the same. Skywords is controlled by Michael Davis, the Company’s Chairman of the Board of Directors and largest stockholder. 
     
    The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
     
    Item 2.03.
    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
     
    The disclosure in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
     
    Item 5.02.
    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    Effective as of June 16, 2025, the Board of Directors (the “Board”) of the Company has renewed the Executive Employment Agreement, dated as of May 7, 2025 (the “Employment Agreement”) with Matthew K. Custer as President and Chief Executive Officer of the Company. The Employment Agreement supersedes any prior employment agreements with the Company.
     
    The term of the Employment Agreement will begin on June 16, 2025 and end on June 16, 2029, followed by successive one-year periods thereafter unless terminated by either party upon 45 days advance written notice. The Employment Agreement provides that Mr. Custer will receive an annual base salary of $225,000 (to be increased to $250,000 when the Company has two consecutive audited break-even quarters), with $200,000 payable in cash and the remaining $25,000 to be delivered in the form of restricted stock units that will vest in equal installments over three years, provided that, in the event of his termination of employment for any reason other than for cause, the award will vest in full upon his termination. Mr. Custer is also eligible to receive a $25,000 signing bonus at the Company’s discretion when it is in a stronger cash position. Under the terms of the Employment Agreement, Mr. Custer will receive a one-time grant of stock options to acquire 150,000 shares of the Company’s common stock (the “Options”) under the Company’s 2016 Equity Incentive Plan on June 16, 2025, subject to the terms of the Plan and a Stock Option Grant Notice and Option Agreement. The exercise price per share of the Options will be the closing market price on the date of the grant. The Options are scheduled to vest in equal installments over three years. Mr. Custer will continue to be eligible to participate in all other employee benefit plans and compensation programs that the Company maintains for salaried employees and executive officers.
     
    If Mr. Custer’s employment is terminated by the Company without cause or Mr. Custer resigns for good reason, subject to Mr. Custer’s execution and non-revocation of a general release of claims against the Company, he will be entitled to receive severance equal to his base salary for 12 months or for the remainder of the term of the Employment Agreement, whichever is less, paid in installments, any accrued but unpaid amount due under the Employment Agreement and continuation of benefits for the applicable severance benefit period. The Employment Agreement includes a six-month post termination non-compete covenant and a five-year post-termination non-disparagement covenant.
     
    The foregoing description of the Employment Agreement is qualified in its entirety by reference to the Employment Agreement, a copy of which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.
     
     

     
     
    Item 9.01
    Financial Statements and Exhibits.
     
    (d) Exhibits
     
    Exhibit
    Number
    Name and/or Identification of Exhibit
    10.1
    Fourth Amendment to Amended and Restated Promissory Note, dated May 2, 2025, by and between Skywords Family Foundation, Inc. and Cyanotech Corporation
    10.2
    Executive Employment Agreement, dated as of May 7, 2025, by and between Matthew K. Custer and Cyanotech Corporation
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    CYANOTECH CORPORATION 
     
           
           
           
    Dated: May 8, 2025 
    /s/ Jennifer C. Rogerson
     
     
    By:
    Jennifer C. Rogerson
     
       
    Chief Financial Officer, Vice President – Finance & Administration, and Treasurer
    (Principal Financial Officer)
     
     
     

     
     
     
    EXHIBIT INDEX
     
    Exhibit
    Number
    Name and/or Identification of Exhibit
    10.1
    Fourth Amendment to Amended and Restated Promissory Note, dated May 2, 2025, by and between Skywords Family Foundation, Inc. and Cyanotech Corporation
    10.2
    Executive Employment Agreement, dated as of May 7, 2025, by and between Matthew K. Custer and Cyanotech Corporation
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     
     
     
    Get the next $CYAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CYAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Davis Michael A / was granted 13,158 units of Cyanotech Corporation Common Stock and bought $3,800 worth of Cyanotech Corporation Common Stock (5,000 units at $0.76) (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    10/3/24 3:27:06 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Davis Michael A / bought $7,650 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    10/1/24 4:42:34 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Davis Michael A / bought $7,700 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    9/27/24 1:33:41 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CFO, VP Fin & Admin, Treasurer Miyashiro Jennifer A.S.

    4 - CYANOTECH CORP (0000768408) (Issuer)

    9/16/25 3:40:05 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Miyashiro Jennifer A.S.

    3 - CYANOTECH CORP (0000768408) (Issuer)

    9/12/25 3:24:28 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Mulder David M was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 33% to 203,468 units (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    9/2/25 6:19:32 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    SEC Filings

    View All

    SEC Form 10-Q filed by Cyanotech Corporation

    10-Q - CYANOTECH CORP (0000768408) (Filer)

    11/10/25 4:02:12 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - CYANOTECH CORP (0000768408) (Filer)

    9/2/25 9:30:08 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events

    8-K - CYANOTECH CORP (0000768408) (Filer)

    8/22/25 6:01:46 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter of fiscal year 2026, ended September 30, 2025. Commenting on the second quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Our second quarter reflected continued momentum in both sales growth and profitability. Total sales increased 19.3% year-over-year, driven by higher bulk sales and strong performance in our online channels. "We also saw meaningful improvement in gross margin as our production volumes continued to increase, driving lower per

    11/10/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the First Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2026, ended June 30, 2025. Commenting on the first quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "While top-line revenue remained relatively flat compared to the prior year, I am encouraged by the meaningful improvement in both gross margin and net loss reduction. Our margin expansion, from 25.0% in the prior year to 30.5%, reflects the continuation of strong operational discipline and improved production efficiency." "We re

    8/6/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2025

    Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2025, ended March 31, 2025. Commenting on the fiscal year results (changes shown vs. fiscal 2024), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Fiscal 2025 was a year of meaningful progress for Cyanotech. Revenue grew 5%, gross margin improved by nearly 3 points and we reduced our operating loss by almost 45%." "Looking ahead, we remain cautious. Economic uncertainty, shifting demand and potential new tariffs could impact costs and global markets. W

    6/20/25 12:00:00 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Leadership Updates

    Live Leadership Updates

    View All

    Cyanotech Corporation Positions for Accelerated Global Growth in Microalgae Market with Key Leadership Appointment

    Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae

    8/1/23 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Financials

    Live finance-specific insights

    View All

    Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter of fiscal year 2026, ended September 30, 2025. Commenting on the second quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Our second quarter reflected continued momentum in both sales growth and profitability. Total sales increased 19.3% year-over-year, driven by higher bulk sales and strong performance in our online channels. "We also saw meaningful improvement in gross margin as our production volumes continued to increase, driving lower per

    11/10/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the First Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2026, ended June 30, 2025. Commenting on the first quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "While top-line revenue remained relatively flat compared to the prior year, I am encouraged by the meaningful improvement in both gross margin and net loss reduction. Our margin expansion, from 25.0% in the prior year to 30.5%, reflects the continuation of strong operational discipline and improved production efficiency." "We re

    8/6/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2025

    Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2025, ended March 31, 2025. Commenting on the fiscal year results (changes shown vs. fiscal 2024), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Fiscal 2025 was a year of meaningful progress for Cyanotech. Revenue grew 5%, gross margin improved by nearly 3 points and we reduced our operating loss by almost 45%." "Looking ahead, we remain cautious. Economic uncertainty, shifting demand and potential new tariffs could impact costs and global markets. W

    6/20/25 12:00:00 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

    SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

    10/3/24 6:39:03 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

    SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

    9/12/24 12:25:52 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

    SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

    9/6/24 12:45:58 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care